{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T04:59:35Z","timestamp":1772600375402,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,3]]},"DOI":"10.7759\/cureus.104638","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T04:04:10Z","timestamp":1772597050000},"source":"Crossref","is-referenced-by-count":0,"title":["The Spectrum of Uncommon Adverse Effects in Patients Treated With Levetiracetam"],"prefix":"10.7759","author":[{"given":"Jayaram","family":"Saibaba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murugesan","family":"Subramaniam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arunprakash","family":"Thangavelu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krithikaa","family":"Chitharanjan Rennukaranjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252941.50833.4a","article-title":"Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy","volume":"68","author":"Brodie MJ","year":"2007","unstructured":"Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007, 68:402-8. 10.1212\/01.wnl.0000252941.50833.4a","journal-title":"Neurology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443110-00002","article-title":"Clinical pharmacokinetics of levetiracetam","volume":"43","author":"Patsalos PN","year":"2004","unstructured":"Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004, 43:707-24. 10.2165\/00003088-200443110-00002","journal-title":"Clin Pharmacokinet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch BA","year":"2004","unstructured":"Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004, 101:9861-6. 10.1073\/pnas.0308208101","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2007.11.021","article-title":"SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy","volume":"54","author":"Kaminski RM","year":"2008","unstructured":"Kaminski RM, Matagne A, Leclercq K, et al.. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology. 2008, 54:715-20. 10.1016\/j.neuropharm.2007.11.021","journal-title":"Neuropharmacology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s1059-1311(03)00111-0","article-title":"Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam","volume":"13","author":"Mula M","year":"2004","unstructured":"Mula M, Trimble MR, Sander JW. Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizure. 2004, 13:55-7. 10.1016\/s1059-1311(03)00111-0","journal-title":"Seizure"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2014.06.004","article-title":"Behavioral side-effects of levetiracetam in children with epilepsy: a systematic review","volume":"23","author":"Halma E","year":"2014","unstructured":"Halma E, de Louw AJ, Klinkenberg S, Aldenkamp AP, IJff DM, Majoie M. Behavioral side-effects of levetiracetam in children with epilepsy: a systematic review. Seizure. 2014, 23:685-91. 10.1016\/j.seizure.2014.06.004","journal-title":"Seizure"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2008.05.012","article-title":"Positive and negative psychotropic effects of levetiracetam","volume":"13","author":"Helmstaedter C","year":"2008","unstructured":"Helmstaedter C, Fritz NE, Kockelmann E, Kosanetzky N, Elger CE. Positive and negative psychotropic effects of levetiracetam. Epilepsy Behav. 2008, 13:535-41. 10.1016\/j.yebeh.2008.05.012","journal-title":"Epilepsy Behav"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2010.0343","article-title":"A case of\u00a0levetiracetam-induced thrombocytopenia","volume":"12","author":"Oghlakian R","year":"2010","unstructured":"Oghlakian R, Nock C, Koubeissi M. A case of\u00a0levetiracetam-induced thrombocytopenia. Epileptic Disord. 2010, 12:335-7. 10.1684\/epd.2010.0343","journal-title":"Epileptic Disord"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.4561","article-title":"Prediction tools for psychiatric adverse effects after levetiracetam prescription","volume":"76","author":"Josephson CB","year":"2019","unstructured":"Josephson CB, Engbers JD, Jette N, et al.. Prediction tools for psychiatric adverse effects after levetiracetam prescription. JAMA Neurol. 2019, 76:440-6. 10.1001\/jamaneurol.2018.4561","journal-title":"JAMA Neurol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419873518","article-title":"Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience","volume":"12","author":"Steinhoff BJ","year":"2019","unstructured":"Steinhoff BJ, Staack AM. Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience. Ther Adv Neurol Disord. 2019, 12:1756286419873518. 10.1177\/1756286419873518","journal-title":"Ther Adv Neurol Disord"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2006.09.008","article-title":"Effect of lamotrigine on depressive symptoms in adult patients with epilepsy","volume":"10","author":"Ettinger AB","year":"2007","unstructured":"Ettinger AB, Kustra RP, Hammer AE. Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. Epilepsy Behav. 2007, 10:148-54. 10.1016\/j.yebeh.2006.09.008","journal-title":"Epilepsy Behav"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1586\/ern.11.58","article-title":"Sexual and reproductive dysfunction associated with antiepileptic drug use in men with epilepsy","volume":"11","author":"Calabr\u00f2 RS","year":"2011","unstructured":"Calabr\u00f2 RS, Marino S, Bramanti P. Sexual and reproductive dysfunction associated with antiepileptic drug use in men with epilepsy. Expert Rev Neurother. 2011, 11:887-95. 10.1586\/ern.11.58","journal-title":"Expert Rev Neurother"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00973.x","article-title":"Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug levetiracetam","volume":"48","author":"Carunchio I","year":"2007","unstructured":"Carunchio I, Pieri M, Ciotti MT, Albo F, Zona C. Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug levetiracetam. Epilepsia. 2007, 48:654-62. 10.1111\/j.1528-1167.2006.00973.x","journal-title":"Epilepsia"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6526-2","article-title":"Should cognition be screened in new-onset epilepsies? A study in 247 untreated patients","volume":"259","author":"Witt JA","year":"2012","unstructured":"Witt JA, Helmstaedter C. Should cognition be screened in new-onset epilepsies? A study in 247 untreated patients. J Neurol. 2012, 259:1727-31. 10.1007\/s00415-012-6526-2","journal-title":"J Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.14-09-05223.1994","article-title":"Differential expression of synaptic vesicle protein 2 (SV2) isoforms","volume":"14","author":"Bajjalieh SM","year":"1994","unstructured":"Bajjalieh SM, Frantz GD, Weimann JM, McConnell SK, Scheller RH. Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci. 1994, 14:5223-35. 10.1523\/JNEUROSCI.14-09-05223.1994","journal-title":"J Neurosci"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2008.07.145","article-title":"Visualization of SV2A conformations in situ by the use of protein tomography","volume":"375","author":"Lynch BA","year":"2008","unstructured":"Lynch BA, Matagne A, Br\u00e4nnstr\u00f6m A, von Euler A, Jansson M, Hauzenberger E, S\u00f6derh\u00e4ll JA. Visualization of SV2A conformations in situ by the use of protein tomography. Biochem Biophys Res Commun. 2008, 375:491-5. 10.1016\/j.bbrc.2008.07.145","journal-title":"Biochem Biophys Res Commun"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5586","article-title":"Levetiracetam-induced aggression and acute behavioral changes: a case report and literature review","volume":"10","author":"Zhang JF","year":"2022","unstructured":"Zhang JF, Piryani R, Swayampakula AK, Farooq O. Levetiracetam-induced aggression and acute behavioral changes: a case report and literature review. Clin Case Rep. 2022, 10:e05586. 10.1002\/ccr3.5586","journal-title":"Clin Case Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00255.x","article-title":"Effect of levetiracetam on epilepsy-related quality of life","volume":"41","author":"Cramer JA","year":"2000","unstructured":"Cramer JA, Arrigo C, Van Hamm\u00e9e G, Gauer LJ, Cereghino JJ. Effect of levetiracetam on epilepsy-related quality of life. Epilepsia. 2000, 41:868-74. 10.1111\/j.1528-1157.2000.tb00255.x","journal-title":"Epilepsia"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2007.04.008","article-title":"Suicidal ideation in epilepsy and levetiracetam therapy","volume":"11","author":"Mula M","year":"2007","unstructured":"Mula M, Sander JW. Suicidal ideation in epilepsy and levetiracetam therapy. Epilepsy Behav. 2007, 11:130-2. 10.1016\/j.yebeh.2007.04.008","journal-title":"Epilepsy Behav"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/35087000","article-title":"SV2 modulates the size of the readily releasable pool of secretory vesicles","volume":"3","author":"Xu T","year":"2001","unstructured":"Xu T, Bajjalieh SM. SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat Cell Biol. 2001, 3:691-8. 10.1038\/35087000","journal-title":"Nat Cell Biol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14701","article-title":"A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers","volume":"60","author":"Finnema SJ","year":"2019","unstructured":"Finnema SJ, Rossano S, Naganawa M, et al.. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers. Epilepsia. 2019, 60:958-67. 10.1111\/epi.14701","journal-title":"Epilepsia"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/470843-the-spectrum-of-uncommon-adverse-effects-in-patients-treated-with-levetiracetam","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T04:04:11Z","timestamp":1772597051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/470843-the-spectrum-of-uncommon-adverse-effects-in-patients-treated-with-levetiracetam"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.104638","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,3]]}}}